25 results
Comparison of Medicare Claims-based Clostridioides difficile infection classification to chart review using a linked cohort
- Dustin Currie, Chantal Lewis, Kelly Hatfield, Joseph Lutgring, Sophia Kazakova, James Baggs, Lauren Korhonen, Maria Correa, Dana Goodenough, Danyel Olson, Jill Szydlowski, Jasmine Watkins, Ghinwa Dumyati, Scott Fridkin, Christopher Wilson, Sujan Reddy, Alice Guh
-
- Journal:
- Antimicrobial Stewardship & Healthcare Epidemiology / Volume 4 / Issue S1 / July 2024
- Published online by Cambridge University Press:
- 16 September 2024, pp. s61-s62
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Background: Medicare claims are frequently used to study Clostridioides difficile infection (CDI) epidemiology. Categorizing CDI based on location of onset and potential exposure is critical in understanding transmission patterns and prevention strategies. While claims data are well-suited for identifying prior healthcare utilization exposures, they lack specimen collection and diagnosis dates to assign likely location of onset. Algorithms to classify CDI onset and healthcare association using claims data have been published, but the degree of misclassification is unknown. Methods: We linked patients with laboratory-confirmed CDI reported to four Emerging Infections Program (EIP) sites from 2016-2020 to Medicare beneficiaries using residence, birth date, sex, and hospitalization and/or healthcare exposure dates. Uniquely linked patients with fee-for-service Medicare A/B coverage and complete EIP case report forms were included. Patients with a claims CDI diagnosis code within ±28 days of a positive CDI test reported to EIP were categorized as hospital-onset (HO), long-term care facility onset (LTCFO), or community-onset (CO, either healthcare facility-associated [COHCFA] or community-associated [CA]) using a previously published algorithm based on claim type, ICD-10-CM code position, and duration of hospitalization (if applicable). EIP classifies CDI into these categories using positive specimen collection date and other information from chart review (e.g. admit/discharge dates). We assessed concordance of EIP and claims case classifications using Cohen’s kappa. Results: Of 10,002 eligible EIP-identified CDI cases, 7,064 were linked to a unique beneficiary; 3,451 met Medicare A/B fee-for-service coverage inclusion criteria. Of these, 650 (19%) did not have a claims diagnosis code ±28 days of the EIP specimen collection date (Table); 48% (313/650) of those without a claims diagnosis code were categorized by EIP as CA CDI. Among those with a CDI diagnosis code, concurrence of claims-based and EIP CDI classification was 68% (κ=0.56). Concurrence was highest for HO and lowest for COHCFA CDI. A substantial number of EIP-classified CO CDIs (30%, Figure) were misclassified as HO using the claims-based algorithm; half of these had a primary ICD-10 diagnosis code of sepsis (226/454; 50%). Conclusions: Evidence of CDI in claims data was found for 81% of EIP-reported CDI cases. Medicare classification algorithms concurred with the EIP classification in 68% of cases. Discordance was most common for community-onset CDI patients, many of whom were hospitalized with a primary diagnosis of sepsis. Misclassification of CO-CDI as HO may bias findings of claims-based CDI studies.
Extended-Spectrum Beta-Lactamase Producing Enterobacterales Infections in the United States, 2012-2021
- Alexander Maillis, Natalie McCarthy, Hannah Wolford, James Baggs, Sujan Reddy, Joseph Lutgring
-
- Journal:
- Antimicrobial Stewardship & Healthcare Epidemiology / Volume 4 / Issue S1 / July 2024
- Published online by Cambridge University Press:
- 16 September 2024, pp. s32-s33
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Background: The 2022 Special Report: COVID-19 U.S. Impact on Antimicrobial Resistance identified continued increases in the rate of extended- spectrum beta-lactamase producing (ESBL) infections in the United States from 2017 through 2020. Using similar data sources and methodology, we examined the trends of species-specific ESBL infections from 2012-2021. Methods: We identified a cohort of patients from the PINC AI and BD Research Insights databases with a clinical culture yielding a Klebsiella pneumoniae or Escherichia coli isolate with accompanying susceptibility testing. E. coli or K. pneumoniae isolates non-susceptible to ceftriaxone, cefotaxime, ceftazidime, or cefepime were considered suggestive of ESBL production. Isolates from patients with no culture yielding the same resistance phenotype of interest in the previous 14 days were counted as an incident case. Community-onset (CO) cultures were obtained ≤ day 3 of hospitalization; hospital-onset (HO) cultures were obtained ≥ day 4. We used a raking procedure to determine weights for extrapolating the number of discharges included in our sample to match the distribution of discharges, stratified by bed size, U.S. census division, urban/rural designation, and teaching status, for U.S. hospitals included in the American Hospital Association survey. We evaluated rates over time due to the changes in number of hospitalizations during the COVID-19 pandemic. Results were stratified by HO and CO, and sterile and non-sterile specimen sources. Results: In 2021, there were 48,936 ESBL K. pneumoniae and 153,112 ESBL E. coli infections among approximately 32 million discharges. Overall, most infections were CO and from non-sterile specimens. From 2012-2021, the rate of ESBL K. pneumoniae increased from 9.54 to 15.28 per 10,000 discharges. ESBL E. coli infections increased from 2012-2020 (30.18 to 51.32 per 10,000 discharges), then declined in 2021 (47.81 per 10,000 discharges) (Table 1, Figure 1). The proportion of non-sterile ESBL E. coli declined from 88% in 2012 to 83% in 2021, and the proportion of non-sterile ESBL K. pneumoniae was 85-87% over the study period (Figure 2). Conclusion: ESBL E. coli and K. pneumoniae infections increased from 2012-2021, although the CO ESBL E. coli rate decreased between 2020 and 2021. Understanding changes in culturing practices over time may provide insights into the increased proportion of ESBL E. coli from sterile sites. Additionally, further investigation into differences in organism trends, particularly in 2021, may inform prevention strategies.
Viral Kinetics of SARS-CoV-2 in Nursing Home Residents and Staff
- Majerle Reeves, Scott Fridkin, Rachel Slayton, Yasin Abul, Christopher Crnich, Jazmin Duque, Jon Furuno, Stefan Gravenstein, Steven Handler, Jennifer Harcourt, Jessica Healy, Marc Lipsitch, Joseph Lutgring, Jennifer Meddings, Jennifer Meece, Lona Mody, David Nace, Prabasaj Paul, Paulina A. Rebolledo, Tiffany Harris, Morgan Katz, Sujan Reddy, David Canaday
-
- Journal:
- Antimicrobial Stewardship & Healthcare Epidemiology / Volume 4 / Issue S1 / July 2024
- Published online by Cambridge University Press:
- 16 September 2024, pp. s73-s74
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Background: Nursing home (NH) residents are at high risk of COVID-19 from exposure to infected staff and other residents. Understanding SARS-CoV-2 viral RNA kinetics in residents and staff can guide testing, isolation, and return to work recommendations. We sought to determine the duration of antigen test and polymerase chain reaction (PCR) positivity in a cohort of NH residents and staff. Methods: We prospectively collected data on SARS-CoV-2 viral kinetics from April 2023 through November 2023. Staff and residents could enroll prospectively or upon a positive test (identified through routine clinical testing, screening, or outbreak response testing). Participating facilities performed routine clinical testing; asymptomatic testing of contacts was performed within 48 hours if an outbreak or known exposure occurred and upon (re-) admission. Enrolled participants who tested positive for SARS-CoV-2 were re-tested daily for 14 days with both nasal antigen and nasal PCR tests. All PCR tests were run by a central lab with the same assay. We conducted a Kaplan-Meier survival analysis on time to first negative test restricted to participants who initially tested positive (day zero) and had at least one test ≥10 days after initially testing positive with the same test type; a participant could contribute to both antigen and PCR survival curves. We compared survival curves for staff and residents using the log-rank test. Results: Twenty-four nursing homes in eight states participated; 587 participants (275 residents, 312 staff) enrolled in the evaluation, participants were only tested through routine clinical or outbreak response testing. Seventy-two participants tested positive for antigen; of these, 63 tested PCR-positive. Residents were antigen- and PCR-positive longer than staff (Figure 1), but this finding is only statistically significant (p=0.006) for duration of PCR positivity. Five days after the first positive test, 56% of 50 residents and 59% of 22 staff remained antigen-positive; 91% of 44 residents and 79% of 19 staff were PCR-positive. Ten days after the first positive test, 22% of 50 residents and 5% of 22 staff remained antigen-positive; 61% of 44 residents and 21% of 19 staff remained PCR-positive. Conclusions: Most NH residents and staff with SARS-CoV-2 remained antigen- or PCR-positive 5 days after the initial positive test; however, differences between staff and resident test positivity were noted at 10 days. These data can inform recommendations for testing, duration of NH resident isolation, and return to work guidance for staff. Additional viral culture data may strengthen these conclusions.
Disclosure: Stefan Gravenstein: Received consulting and speaker fees from most vaccine manufacturers (Sanofi, Seqirus, Moderna, Merck, Janssen, Pfizer, Novavax, GSK, and have or expect to receive grant funding from several (Sanofi, Seqirus, Moderna, Pfizer, GSK). Lona Mody: NIH, VA, CDC, Kahn Foundation; Honoraria: UpToDate; Contracted Research: Nano-Vibronix
Utilization of multiplex molecular panels for urinary tract infections, Medicare claims, 2016 – 2022
- Kelly Hatfield, Sarah Kabbani, Dustin Currie, Christine Kim, Isaac See, Kara Jacobs Slifka, Shelley Magill, Lauri Hicks, Lawrence McDonald, John Jernigan, Sujan Reddy, Joseph Lutgring
-
- Journal:
- Antimicrobial Stewardship & Healthcare Epidemiology / Volume 4 / Issue S1 / July 2024
- Published online by Cambridge University Press:
- 16 September 2024, p. s78
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Background: Multiplex molecular tests for infectious diseases can provide highly sensitive results rapidly; however, these tests may more readily detect asymptomatic colonization. There are reports of non-FDA approved laboratory-developed multiplex tests for the diagnosis of urinary tract infections (UTI). Differentiating UTI from asymptomatic bacteriuria is challenging, especially in older adults. The increased sensitivity of multiplex tests may exacerbate this challenge. We sought to describe the use of multiplex testing for UTIs in Medicare claims. Methods: Multiplex testing was identified using carrier claims submitted by non-institutional providers using the Chronic Conditions Warehouse for 2016 – 2022. Because there are no CPT-4 codes specifying UTI multiplex testing, we included claims as described in Figure 1 and categorized claims based on the primary ICD-10-CM diagnosis. The payment amounts for line items related to testing for infectious agents were summed. Laboratories were counted using CLIA numbers listed on corresponding claims. Beneficiaries residing in a nursing home at the time of their claim were identified using stay information derived from the Minimum Dataset 3.0. For comparison, similar characteristics among carrier claims with a CPT-4 code indicating urine culture were also described. Results: Claims for unspecified multiplex molecular tests overall have increased, driven by increases in claims with a primary UTI diagnosis (from 8,521 in 2016 to 386,943 in 2022), while urine cultures have not (Figure 1). In 2022, 65% of all unspecified multiplex tests were linked to a diagnosis of UTI; UTI multiplex claims were associated with 647 laboratories. For UTI claims, the median cost per claim for line items related to multiplex testing was $589 compared to $13 for urine culture-related line items. Overall, 8% of UTI multiplex claims were for beneficiaries residing in a nursing home. Conclusions: Claims for non-FDA approved unspecified multiplex tests associated with a primary diagnosis of UTI have increased >45-times between 2016-2021 and have >45-times higher median costs than urine cultures. The use of this testing in the Medicare population, including nursing home residents, is of potential concern given that inappropriate treatment of asymptomatic bacteriuria has been described to be common in older adults. Research is needed to outline use cases where UTI multiplex testing may be beneficial. Appropriate use of diagnostic testing is important to minimize diagnostic errors and avoid unnecessary antibiotic use.
Organism-specific Trends in Carbapenem-resistant Enterobacterales Infections in a Cohort of Hospitalized Patients, 2012–2022
- Mohammed Khan, Hannah Wolford, Natalie McCarthy, Babatunde Olubajo, Jonathan Bishop, James Baggs, Joseph Lutgring, Sujan Reddy, Maroya Walters
-
- Journal:
- Antimicrobial Stewardship & Healthcare Epidemiology / Volume 4 / Issue S1 / July 2024
- Published online by Cambridge University Press:
- 16 September 2024, p. s156
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Background: Carbapenem-resistant Enterobacterales (CRE) infections are an urgent public health threat. An estimated 12,700 CRE (including E. coli, Klebsiella spp., and Enterobacter spp.) infections occurred in the United States in 2020. While the estimated incidence of CRE infections has been relatively stable between 2012 and 2020, organism-specific trends, including those for organisms not typically included in CRE surveillance definitions, have not been described. We estimated the annual rate of carbapenem-resistant Enterobacterales infections, disaggregated by organism, from 2012 to 2022. Methods: Data on inpatient hospitalizations from a dynamic cohort of short-term acute care hospitals reporting microbiology data between 2012 and 2022 were obtained from the PINC AI Database and the BD Insights Research Database. We included patients with clinical isolates of E. coli, Enterobacter spp., Klebsiella spp., Citrobacter spp., Serratia marcescens, Proteus mirabilis, and Morganella spp. and sufficient susceptibility results to identify carbapenem resistance. We limited our analysis to incident isolates, defined as a patient’s first isolate of a given organism and carbapenem resistance phenotype in a 14-day period. We calculated the annual rate of carbapenem-resistant infections per 10,000 hospitalizations for each organism. Results: There were 3,018,792 incident isolates from 55.8 million hospitalizations included in the analysis. Overall, 31,226 incident carbapenem-resistant isolates were identified. The rate of carbapenem-resistant infections varied by organism and over time (Table 1). The rate of carbapenem-resistant Klebsiella spp. infections appeared to decline from 3.94 in 2012 to 2.44 infections per 10,000 hospitalizations in 2022. The rate of carbapenem-resistant Enterobacter spp. infections appeared to increase from 1.05 in 2012 to 1.44 infections per 10,000 hospitalizations in 2022. The rate of carbapenem-resistant E. coli infections also appeared to increase, from 0.61 in 2012 to 0.85 infections per 10,000 hospitalizations in 2022. Rates of carbapenem-resistant Proteus mirabilis, Morganella spp., Citrobacter spp., or Serratia marcescens infections were similar in 2022 compared to 2012. Conclusions: Disaggregating data by organism revealed heterogeneous trends, with apparent increases in rates of carbapenem-resistant Enterobacter spp. and E. coli infections and apparent decreases in rates of carbapenem-resistant Klebsiella spp. infections. Organism-specific CRE analyses may provide additional insight into CRE epidemiology.
Length of antibiotic therapy among adults hospitalized with uncomplicated community-acquired pneumonia, 2013–2020
- Natalie L. McCarthy, James Baggs, Hannah Wolford, Sophia V. Kazakova, Sarah Kabbani, Brandon K. Attell, Melinda M. Neuhauser, Lindsey Walker, Sarah H. Yi, Kelly M. Hatfield, Sujan Reddy, Lauri A. Hicks
-
- Journal:
- Infection Control & Hospital Epidemiology / Volume 45 / Issue 6 / June 2024
- Published online by Cambridge University Press:
- 14 February 2024, pp. 726-732
- Print publication:
- June 2024
-
- Article
- Export citation
-
Objective:
The 2014 US National Strategy for Combating Antibiotic-Resistant Bacteria (CARB) aimed to reduce inappropriate inpatient antibiotic use by 20% for monitored conditions, such as community-acquired pneumonia (CAP), by 2020. We evaluated annual trends in length of therapy (LOT) in adults hospitalized with uncomplicated CAP from 2013 through 2020.
Methods:We conducted a retrospective cohort study among adults with a primary diagnosis of bacterial or unspecified pneumonia using International Classification of Diseases Ninth and Tenth Revision codes in MarketScan and the Centers for Medicare & Medicaid Services databases. We included patients with length of stay (LOS) of 2–10 days, discharged home with self-care, and not rehospitalized in the 3 days following discharge. We estimated inpatient LOT based on LOS from the PINC AI Healthcare Database. The total LOT was calculated by summing estimated inpatient LOT and actual postdischarge LOT. We examined trends from 2013 to 2020 in patients with total LOT >7 days, which was considered an indicator of likely excessive LOT.
Results:There were 44,976 and 400,928 uncomplicated CAP hospitalizations among patients aged 18–64 years and ≥65 years, respectively. From 2013 to 2020, the proportion of patients with total LOT >7 days decreased by 25% (68% to 51%) among patients aged 18–64 years and by 27% (68%–50%) among patients aged ≥65 years.
Conclusions:Although likely excessive LOT for uncomplicated CAP patients decreased since 2013, the proportion of patients treated with LOT >7 days still exceeded 50% in 2020. Antibiotic stewardship programs should continue to pursue interventions to reduce likely excessive LOT for common infections.
Uncovering gut microbiota-mediated indirect effects of antibiotic use on Clostridioides difficile transmission
- Camden Gowler, Prabasaj Paul, Mihnea Mangalea, Daniel Nkemzi, Hannah Wolford, Sujan Reddy, Alison Halpin, Lawrence McDonald, Rachel Slayton
-
- Journal:
- Antimicrobial Stewardship & Healthcare Epidemiology / Volume 3 / Issue S2 / June 2023
- Published online by Cambridge University Press:
- 29 September 2023, pp. s104-s105
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Background: Clostridioides difficile and multidrug-resistant organisms (MDROs) pose challenges due to treatment complexities and substantial morbidity and mortality. Susceptibility to colonization with these organisms and potential onward transmission if colonized (ie, infectivity) is influenced by the human microbiome and its dynamics. Disruptive effects of antibiotics on the microbiome imply potential indirect effects of antibiotics on C. difficile colonization. Mathematical models can help explore the relative impact of key pathways linking antibiotic use to C. difficile colonization, including the relationship between population-level antibiotic use and colonization prevalence. Methods: We built a compartmental model of long-term C. difficile colonization prevalence of nursing home residents (though malleable for any MDRO), allowing interactions between the microbiome and the colonization process. Based on proportional abundance of microbial taxa, we classified individuals into high and low α diversity groups, each further stratified into uncolonized or colonized with C. difficile. The rate of transition from the high to low microbiome diversity group was proportional to the population-level rate of antibiotic use. Transmission dynamics followed a susceptible–infectious–susceptible framework with the possibility for increased susceptibility and infectivity for the low-diversity microbiome group. First, as a comparator, we used a “null model” in which microbiome diversity did not influence host susceptibility or infectivity. Next, we sampled from realistic (literature informed) parameter ranges to analyze how the microbiome mediates the effect of antibiotics on colonization in this population. Results: Our analysis suggests that antibiotic use can catalyze colonization with C. difficile through interactions with the host microbiome, resulting in a sharp increase in colonization with a modest increase in antibiotic use (Fig 1). Increasing the population-level antibiotic use by 5% led to a median 24% increase in long-term colonization prevalence in the model (Fig 2). In contrast, increasing susceptibility or infectivity rates by 5% resulted in slightly higher increases in total colonization (27% and 29%, respectively). However, there was considerable uncertainty around these estimates, with interquartile ranges of up to 20% for some parameters (Fig 2). Conclusions: Higher population-level antibiotic use likely increases colonization by C. difficile through indirect effects of the microbiome. The increased colonization burden attributable to increasing antibiotic use may be substantial. With high uncertainty around some estimates, conducting observational studies to better understand key colonization and microbiome parameters (eg, the relative increase in susceptibility or infectivity with lower microbiome diversity) is critical for future efforts to estimate the impact of antibiotic use on colonization with C. difficile and MDROs.
Disclosures: None
Fluconazole resistance in non-albicans Candida species in the United States, 2012-2021
- Emily Jenkins, Meghan Lyman, Brendan Jackson, Shawn Lockhart, Hannah Wolford, Sujan Reddy, James Baggs
-
- Journal:
- Antimicrobial Stewardship & Healthcare Epidemiology / Volume 3 / Issue S2 / June 2023
- Published online by Cambridge University Press:
- 29 September 2023, pp. s29-s30
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Background: Candida spp can cause a variety of infections known as candidiasis, ranging from severe invasive infections to superficial mucosal infections of the mouth and vagina. Fluconazole, a triazole antifungal, is commonly prescribed to treat candidiasis but increasing fluconazole resistance is a growing concern for several Candida spp. Although C. albicans has historically been the most common cause of candidiasis, other species are increasingly common and antifungal resistance is more prevalent in these non-albicans species, including C. glabrata, C. parapsilosis, and C. tropicalis, which were the focus of this analysis. Methods: We used the PINC AI healthcare data (PHD) database to examine fluconazole resistance for inpatient isolates between 2012 and 2021 from 187 US acute-care hospitals with at least 1 Candida spp culture with a fluconazole susceptibility result over the entire period. We calculated annual percentage fluconazole resistance for C. glabrata, C. tropicalis, and C. parapsilosis isolates using the clinical laboratory interpretation for resistance. Results: We identified 4,264 C. glabrata, 2,482 C. parapsilosis, and 2,283 C. tropicalis isolates between 2012 and 2021 with susceptibility results. The percentage of C. glabrata isolates resistant to fluconazole doubled between 2020 and 2021 (14.6% vs 29.3%) (Fig. 1a). The percentage of C. parapsilosis isolates resistant to fluconazole steadily increased since 2017 (Fig. 1b), with an 82% increase in 2021 compared with 2020 (3.8% in 2020 vs 6.9% in 2021). Fluconazole resistance among C. tropicalis isolates varied over the years, with a 0.3% decrease in 2021 from 2020 (Fig. 1c). Of hospitals reporting at least 1 result each year 2020–2021, 44% observed an increase in the proportion of C. glabrata isolates resistant to fluconazole in 2021 compared to 2020. Conclusions: Our analysis highlights a concerning increase in fluconazole resistance among C. glabrata and C. parapsilosis isolates in 2021 compared with previous years. Further investigation of the observed increases in fluconazole resistance among these Candida spp could provide further insight on potential drivers of resistance or limitations in reported results from large databases. More analyses are needed to understand rates, sites of Candida infections, and risk factors (eg, antifungal exposure) associated with resistance.
Disclosures: None
Decolonization of hospital patients may aid efforts to reduce transmission of carbapenem-resistant Enterobacterales
- Brajendra K. Singh, Prabasaj Paul, Camden D. Gowler, Sujan C. Reddy, Rachel B. Slayton
-
- Journal:
- Antimicrobial Stewardship & Healthcare Epidemiology / Volume 3 / Issue S2 / June 2023
- Published online by Cambridge University Press:
- 29 September 2023, pp. s59-s60
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Background: Multimodal approaches are often used to prevent transmission of antimicrobial-resistant pathogens among patients in healthcare settings; understanding the effect of individual interventions is challenging. We designed a model to compare the effectiveness of hand hygiene (HH) with or without decolonization in reducing patient colonization with carbapenem-resistant Enterobacterales (CRE). Methods: We developed an agent-based model to represent transmission of CRE in an acute-care hospital comprising 3 general wards and 2 ICUs, each with 20 single-occupancy rooms, located in a community of 85,000 people. The model accounted for the movement of healthcare personnel (HCP), including their visits to patients. CRE dynamics were modeled using a susceptible–infectious–susceptible framework with transmission occurring via HCP–patient contacts. The mean time to clearance of CRE colonization without intervention was 387 days (Zimmerman et al, 2013). Our baseline included a facility-level HH compliance of 30%, with an assumed efficacy of 50%. Contact precautions were employed for patients with CRE-positive cultures with assumed adherence and efficacy of 80% and 50%, respectively. Intervention scenarios included decolonization of culture-positive CRE patients, with a mean time to decolonization of 3 days. We considered 2 hypothetical intervention scenarios: (A) decolonization of patients with the baseline HH compliance and (B) decolonization with a slightly improved HH compliance of 35%. The hospital-level CRE incidence rate was used to compare the results from these intervention scenarios. Results: CRE incidence rates were lower in intervention scenarios than the baseline scenario (Fig. 1). The baseline mean incidence rate was 29.1 per 10,000 patient days. For decolonization with the baseline HH, the mean incidence rate decreased to 14.5 per 10,000 patient days, which is a 50.2% decrease relative to the baseline incidence (Table 1). The decolonization scenario with a slightly improved HH compliance of 35% produced a relative reduction of 71.9% relative to the baseline incidence. Conclusions: Our analysis shows that decolonization, combined with modest improvement in HH compliance, could lead to large decreases in pathogen transmission. In turn, this model implies that efforts to identify and improve decolonization strategies for better patient safety in health care may be needed and are worth exploring.
Disclosures: None
Empiric antibiotic selection for community-acquired pneumonia in US hospitals, 2013–2020
- Hannah Wolford, Brandon Attell, James Baggs, Sujan Reddy, Sarah Kabbani, Melinda Neuhauser, Lauri Hicks
-
- Journal:
- Antimicrobial Stewardship & Healthcare Epidemiology / Volume 3 / Issue S2 / June 2023
- Published online by Cambridge University Press:
- 29 September 2023, pp. s26-s27
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Background: Community-acquired pneumonia (CAP) is a common indication for antibiotic prescribing in hospitalized patients. Professional societies’ clinical guidelines recommend specific antibiotics for empiric treatment of CAP based on clinical factors. Manual assessments of appropriateness are time-consuming and are often conducted on a smaller scale. We evaluated empiric antibiotic selection among a large cohort of adults hospitalized with CAP using electronic health records. Methods: In this study, we used the PINC-AI healthcare database to define a cohort of adults hospitalized with CAP from 2013 to 2020. CAP was identified by International Classification of Diseases (ICD) diagnosis codes. Exclusions were applied to identify uncomplicated CAP (Fig. 1). Treatment was only evaluated if a chest radiograph or computerized tomography (CT) scan was charged during the first 2 days of hospitalization, otherwise it was considered an inadequate CAP evaluation. Administrative billing data were used to identify antibiotics charged within the first 2 days of hospitalization. Empiric guideline-recommended treatment was determined based on 2019 CAP guidelines and more recent studies. Patients who received nonrecommended treatment were evaluated for antibiotic allergies in the current hospitalization or methicillin-resistant Staphylococcus aureus (MRSA) colonization or infection in the year prior or on admission using International Classification of Disease, Tenth Revision (ICD-10) diagnosis codes. Results: We identified 4.47 million adult hospitalizations with CAP from 2013 to 2020; 32% (1.43 million) were included in this analysis (Fig. 1). Among discharges with adequate CAP evaluation (1.37 million), 59.7% received recommended antibiotics in the first 2 days of hospitalization, ranging from 62.6% in 2013 to 57.5% in 2019. Overall, 34.8% of our study population received a nonrecommended antibiotic without documentation of an antibiotic allergy or MRSA colonization (2013: 32.5%; 2018: 36.7%) (Fig. 2). Most patients in our study population received >1 antibiotic (92.3%) in the first 2 days of hospitalization. The most common antibiotics among patients receiving recommended treatment were ceftriaxone (74.2% of patients receiving recommended treatment), azithromycin (67.2%), and levofloxacin (31.8%) (Fig. 3a). The most common nonrecommended antibiotics were vancomycin (57.2% of patients receiving nonrecommended treatment), piperacillin-tazobactam (48.1%), and cefepime (25.7%) (Fig. 3b). From 2013 to 2020, cefepime charges consistently increased among CAP patients treated with nonrecommended antibiotics, whereas levofloxacin charges consistently decreased among CAP patients treated with only recommended antibiotics. Conclusions: Approximately one-third of patients with uncomplicated CAP received nonrecommended empiric antibiotics, and from 2013 to 2020 that proportion increased by 9%. Additional strategies are needed to help identify opportunities to optimize antibiotic selection among patients with CAP.
Disclosures: None
Length of antibiotic therapy among adults aged ≥65 years hospitalized with uncomplicated community-acquired pneumonia, 2013-2020
- Natalie McCarthy, Hannah Wolford, Sophia Kazakova, James Baggs, Brandon Attell, Sarah Kabbani, Melinda Neuhauser, Sarah Yi, Kelly Hatfield, Sujan Reddy, Lauri Hicks
-
- Journal:
- Antimicrobial Stewardship & Healthcare Epidemiology / Volume 3 / Issue S2 / June 2023
- Published online by Cambridge University Press:
- 29 September 2023, p. s26
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Background: The 2014 US National Strategy for Combating Antibiotic-Resistant Bacteria aimed to reduce inappropriate inpatient antibiotic use by 20% for monitored conditions, such as community-acquired pneumonia (CAP), by 2020. Clinical guidelines recommend treating uncomplicated CAP with a minimum of 5 days of antibiotic therapy. Total length of therapy (LOT) >7 days or >3 days after clinical improvement is rarely necessary. In a previous study estimating LOT in uncomplicated CAP patients, 71% of patients ≥65 years exceeded recommended duration of antibiotics in 2012–2013 (Yi et al, 2018). We evaluated annual trends in LOT in adults ≥65 years hospitalized with uncomplicated CAP from 2013 to 2020. Methods: We conducted a retrospective cohort study among patients in the CMS database with a primary diagnosis of bacterial or unspecified pneumonia using International Classification of Diseases 9th and 10th Revision codes, length of stay (LOS) of 2–10 days, discharged home with self-care, and not rehospitalized in the 3 days following discharge. Discharge home was used as a surrogate for clinical improvement. Because inpatient LOT is not available in CMS data, we used linear regression to model inpatient LOT as a function of LOS using data on CAP patients ≥65 years from the PINC AI healthcare database. Postdischarge LOT was based on prescriptions filled following discharge. Total LOT was calculated by summing estimated inpatient LOT and actual postdischarge LOT (Fig. 1). Total LOT >7 days and postdischarge LOT >3 days were considered indicators of likely excessive LOT. We reported trends in the proportion of patients with likely excessive LOT during the study period. Results: From 2013 through 2020, there were 400,928 uncomplicated CAP hospitalizations among patients aged ≥65 years. Patients were more likely to be female (55%), and they had a median age of 76 years and a median LOS of 3 days. The median total LOT decreased from 9.5 days in 2013 to 7.7 days in 2020. The proportion of patients with total LOT >7 days decreased from 68% in 2013 to 50% in 2020 (% change, −27%); the proportion with postdischarge LOT >3 days decreased from 73% in 2013 to 62% in 2020 (% change, −16%) (Fig. 2). Conclusions: Likely excessive total LOT for adults ≥65 years hospitalized with uncomplicated CAP decreased by 27% in 2020, a considerable improvement from 2013. However, the high proportion of patients with likely excessive postdischarge LOT in 2020 (62%) demonstrates the need for antibiotic stewardship to optimize prescribing at hospital discharge.
Disclosures: None
Characteristics of nursing home residents and healthcare personnel with repeated severe acute respiratory coronavirus virus 2 (SARS-CoV-2) tests positive ≥90 days after initial infection: Four US jurisdictions, July 2020–March 2021
- Part of
- W. Wyatt Wilson, Kelly M. Hatfield, Stacy Tressler, Cara Bicking Kinsey, Gemma Parra, Renée Zell, Anitra Denson, Channyn Williams, Kevin B. Spicer, Ishrat Kamal-Ahmed, Baha Abdalhamid, Mahlet Gemechu, Jennifer Folster, Natalie J. Thornburg, Azaibi Tamin, Jennifer L. Harcourt, Krista Queen, Suxiang Tong, John A. Jernigan, Matthew Crist, Kiran M. Perkins, Sujan C. Reddy, for the Repeat Positive SARS-CoV-2 Test After 90 Days (REPOST-90) Study Team
-
- Journal:
- Infection Control & Hospital Epidemiology / Volume 44 / Issue 5 / May 2023
- Published online by Cambridge University Press:
- 20 May 2022, pp. 809-812
- Print publication:
- May 2023
-
- Article
- Export citation
-
One in six nursing home residents and staff with positive SARS-CoV-2 tests ≥90 days after initial infection had specimen cycle thresholds (Ct) <30. Individuals with specimen Ct<30 were more likely to report symptoms but were not different from individuals with high Ct value specimens by other clinical and testing data.
Trends in facility-level rates of Clostridioides difficile infections in US hospitals, 2019–2020
- Ashley N. Rose, James Baggs, Sophia V. Kazakova, Alice Y. Guh, Sarah H. Yi, Natalie L. McCarthy, John A. Jernigan, Sujan C. Reddy
-
- Journal:
- Infection Control & Hospital Epidemiology / Volume 44 / Issue 2 / February 2023
- Published online by Cambridge University Press:
- 19 May 2022, pp. 238-245
- Print publication:
- February 2023
-
- Article
- Export citation
-
Objectives:
The coronavirus disease 2019 pandemic caused substantial changes to healthcare delivery and antibiotic prescribing beginning in March 2020. To assess pandemic impact on Clostridioides difficile infection (CDI) rates, we described patients and trends in facility-level incidence, testing rates, and percent positivity during 2019–2020 in a large cohort of US hospitals.
Methods:We estimated and compared rates of community-onset CDI (CO-CDI) per 10,000 discharges, hospital-onset CDI (HO-CDI) per 10,000 patient days, and C. difficile testing rates per 10,000 discharges in 2019 and 2020. We calculated percent positivity as the number of inpatients diagnosed with CDI over the total number of discharges with a test for C. difficile. We used an interrupted time series (ITS) design with negative binomial and logistic regression models to describe level and trend changes in rates and percent positivity before and after March 2020.
Results:In pairwise comparisons, overall CO-CDI rates decreased from 20.0 to 15.8 between 2019 and 2020 (P < .0001). HO-CDI rates did not change. Using ITS, we detected decreasing monthly trends in CO-CDI (−1% per month, P = .0036) and HO-CDI incidence (−1% per month, P < .0001) during the baseline period, prior to the COVID-19 pandemic declaration. We detected no change in monthly trends for CO-CDI or HO-CDI incidence or percent positivity after March 2020 compared with the baseline period.
Conclusions:While there was a slight downward trajectory in CDI trends prior to March 2020, no significant change in CDI trends occurred during the COVID-19 pandemic despite changes in infection control practices, antibiotic use, and healthcare delivery.
Temporal trends in urine-culture rates in the US acute-care hospitals, 2017–2020
- Sophia Kazakova, Natalie McCarthy, James Baggs, Kelly Hatfield, Babatunde Wolford, Babatunde Olubajo, John Jernigan, Sujan Reddy
-
- Journal:
- Antimicrobial Stewardship & Healthcare Epidemiology / Volume 2 / Issue S1 / July 2022
- Published online by Cambridge University Press:
- 16 May 2022, p. s12
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Background: Previously, we reported decreasing postadmission urine-culture rates in hospitalized patients between 2012 and 2017, indicating a possible decrease in hospital-onset urinary tract infections or changes in diagnostic practices in acute-care hospitals (ACHs). In this study, we re-evaluated the trends using more recent data from 2017–2020 to assess whether new trends in hospital urine-culturing practices had emerged. Method: We conducted a longitudinal analysis of monthly urine-culture rates using microbiology data from 355 ACHs participating in the Premier Healthcare Database in 2017–2020. All cultures from the urinary tract collected on or before day 3 were defined as admission urine cultures and those collected on day 4 or later were defined as postadmission urine cultures. We included discharges from months where a hospital reported at least 1 urine culture with microbiology and antimicrobial susceptibility test results. Annual estimates of rates of admission culture and postadmission urine-culture rates were assessed using general estimating equation models with a negative binomial distribution accounting for hospital-level clustering and adjusting for hospital bed size, teaching status, urban–rural designation, discharge month, and census division. Estimated rate for each year (2018, 2019, and 2020) was compared to previous year’s estimated rate using rate ratios (RRs) and 95% confidence intervals (CIs) generated through the multivariable GEE models. Results: From 2017 to 2020, we included 8.7 million discharges and 1,943,540 urine cultures, of which 299,013 (15.4%) were postadmission urine cultures. In 2017–2020, unadjusted admission culture rates were 20.0, 19.6, 17.9, and 18.2 per 100 discharges respectively; similarly, unadjusted postadmission urine-culture rates were 8.6, 7.8, 7.0, and 7.5 per 1,000 patient days. In the multivariable analysis, adjusting for hospital characteristics, no significant changes in admission urine-culture rates were detected during 2017–2019; however, in 2020, admission urine-culture rates increased 6% compared to 2019 (RR, 1.06; 95% CI, 1.02–1.09) (Fig. 1). Postadmission urine-culture rates decreased 4% in 2018 compared to 2017 (RR, 0.96; 95% CI, 0.91–0.99) and 8% in 2019 compared to 2018 (RR, 0.92; 95% CI, 0.87–0.96). In 2020, postadmission urine-culture rates increased 10% compared to 2019 (RR, 1.10; 95% CI, 1.06–1.14) (Fig. 2). Factors significantly associated with postadmission urine-culture rates included discharge month and hospital bed size. For admission urine cultures, discharge month was the only significant factor. Conclusions: Between 2017–2019, postadmission urine-culture rates continued a decreasing trend, while admission culture rates remained unchanged. However, in 2020 both admission and postadmission urine culture rates increased significantly in comparison to 2019.
Funding: None
Disclosures: None
Associations of facility-level antibiotic use and hospital-onset Clostridioides difficile infection in US acute-care hospitals, 2012–2018
- Sophia V. Kazakova, James Baggs, Sarah H. Yi, Sujan C. Reddy, Kelly M. Hatfield, Alice Y. Guh, John A. Jernigan, L. Clifford McDonald
-
- Journal:
- Infection Control & Hospital Epidemiology / Volume 43 / Issue 8 / August 2022
- Published online by Cambridge University Press:
- 07 May 2021, pp. 1067-1069
- Print publication:
- August 2022
-
- Article
-
- You have access Access
- Open access
- HTML
- Export citation
-
Previously reported associations between hospital-level antibiotic use and hospital-onset Clostridioides difficile infection (HO-CDI) were reexamined using 2012–2018 data from a new cohort of US acute-care hospitals. This analysis revealed significant positive associations between total, third-generation, and fourth-generation cephalosporin, fluoroquinolone, carbapenem, and piperacillin-tazobactam use and HO-CDI rates, confirming previous findings.
Pediatric research priorities in healthcare-associated infections and antimicrobial stewardship
- Susan E. Coffin, Francisca Abanyie, Kristina Bryant, Joseph Cantey, Anthony Fiore, Stephanie Fritz, Judith Guzman-Cottrill, Adam L. Hersh, W. Charles Huskins, Larry K. Kociolek, Matthew Kronman, Ebbing Lautenbach, Grace Lee, Matthew Linam, Latania K. Logan, Aaron Milstone, Jason Newland, A. Christine Nyquist, Debra L. Palazzi, Sameer Patel, Karen Puopolo, Sujan C. Reddy, Lisa Saiman, Thomas Sandora, Andi L. Shane, Michael Smith, Pranita D. Tamma, Theoklis Zaoutis, Danielle Zerr, Jeffrey S. Gerber, for the CDC Prevention Epicenters Program
-
- Journal:
- Infection Control & Hospital Epidemiology / Volume 42 / Issue 5 / May 2021
- Published online by Cambridge University Press:
- 26 November 2020, pp. 519-522
- Print publication:
- May 2021
-
- Article
- Export citation
-
Objective:
To develop a pediatric research agenda focused on pediatric healthcare-associated infections and antimicrobial stewardship topics that will yield the highest impact on child health.
Participants:The study included 26 geographically diverse adult and pediatric infectious diseases clinicians with expertise in healthcare-associated infection prevention and/or antimicrobial stewardship (topic identification and ranking of priorities), as well as members of the Division of Healthcare Quality and Promotion at the Centers for Disease Control and Prevention (topic identification).
Methods:Using a modified Delphi approach, expert recommendations were generated through an iterative process for identifying pediatric research priorities in healthcare associated infection prevention and antimicrobial stewardship. The multistep, 7-month process included a literature review, interactive teleconferences, web-based surveys, and 2 in-person meetings.
Results:A final list of 12 high-priority research topics were generated in the 2 domains. High-priority healthcare-associated infection topics included judicious testing for Clostridioides difficile infection, chlorhexidine (CHG) bathing, measuring and preventing hospital-onset bloodstream infection rates, surgical site infection prevention, surveillance and prevention of multidrug resistant gram-negative rod infections. Antimicrobial stewardship topics included β-lactam allergy de-labeling, judicious use of perioperative antibiotics, intravenous to oral conversion of antimicrobial therapy, developing a patient-level “harm index” for antibiotic exposure, and benchmarking and or peer comparison of antibiotic use for common inpatient conditions.
Conclusions:We identified 6 healthcare-associated infection topics and 6 antimicrobial stewardship topics as potentially high-impact targets for pediatric research.
Regional Impact of a CRE Intervention Targeting High Risk Postacute Care Facilities (Chicago PROTECT)
- Michael Lin, Mary Carl Froilan, Jinal Makhija, Ellen Benson, Sarah Bartsch, Pamela B. Bell, Stephanie Black, Deborah Burdsall, Michelle Ealy, Anthony Fiore, Sharon Foy, Mabel Frias, Alice Han, David Hines, Olufemi Jegede, John Jernigan, Sarah K. Kemble, Mary Alice Lavin, Bruce Lee, George Markovski, Massimo Pacilli, Sujan Reddy, Erica Runningdeer, Michael Schoeny, Mitali Shah, Rachel Slayton, Elizabeth Soda, Nimalie Stone, Angela S. Tang, Karen Trimberger, Marion Tseng, Yingxu Xiang, Robert Weinstein, William Trick, Mary Hayden
-
- Journal:
- Infection Control & Hospital Epidemiology / Volume 41 / Issue S1 / October 2020
- Published online by Cambridge University Press:
- 02 November 2020, pp. s48-s49
- Print publication:
- October 2020
-
- Article
-
- You have access Access
- Export citation
-
Background: Carbapenem-resistant Enterobacteriaceae (CRE) are endemic in the Chicago region. We assessed the regional impact of a CRE control intervention targeting high-prevalence facilities; that is, long-term acute-care hospitals (LTACHs) and ventilator-capable skilled nursing facilities (vSNFs). Methods: In July 2017, an academic–public health partnership launched a regional CRE prevention bundle: (1) identifying patient CRE status by querying Illinois’ XDRO registry and periodic point-prevalence surveys reported to public health, (2) cohorting or private rooms with contact precautions for CRE patients, (3) combining hand hygiene adherence, monitoring with general infection control education, and guidance by project coordinators and public health, and (4) daily chlorhexidine gluconate (CHG) bathing. Informed by epidemiology and modeling, we targeted LTACHs and vSNFs in a 13-mile radius from the coordinating center. Illinois mandates CRE reporting to the XDRO registry, which can also be manually queried or generate automated alerts to facilitate interfacility communication. The regional intervention promoted increased automation of alerts to hospitals. The prespecified primary outcome was incident clinical CRE culture reported to the XDRO registry in Cook County by month, analyzed by segmented regression modeling. A secondary outcome was colonization prevalence measured by serial point-prevalence surveys for carbapenemase-producing organism colonization in LTACHs and vSNFs. Results: All eligible LTACHs (n = 6) and vSNFs (n = 9) participated in the intervention. One vSNF declined CHG bathing. vSNFs that implemented CHG bathing typically bathed residents 2–3 times per week instead of daily. Overall, there were significant gaps in infection control practices, especially in vSNFs. Also, 75 Illinois hospitals adopted automated alerts (56 during the intervention period). Mean CRE incidence in Cook County decreased from 59.0 cases per month during baseline to 40.6 cases per month during intervention (P < .001). In a segmented regression model, there was an average reduction of 10.56 cases per month during the 24-month intervention period (P = .02) (Fig. 1), and an estimated 253 incident CRE cases were averted. Mean CRE incidence also decreased among the stratum of vSNF/LTACH intervention facilities (P = .03). However, evidence of ongoing CRE transmission, particularly in vSNFs, persisted, and CRE colonization prevalence remained high at intervention facilities (Table 1). Conclusions: A resource-intensive public health regional CRE intervention was implemented that included enhanced interfacility communication and targeted infection prevention. There was a significant decline in incident CRE clinical cases in Cook County, despite high persistent CRE colonization prevalence in intervention facilities. vSNFs, where understaffing or underresourcing were common and lengths of stay range from months to years, had a major prevalence challenge, underscoring the need for aggressive infection control improvements in these facilities.
Funding: The Centers for Disease Control and Prevention (SHEPheRD Contract No. 200-2011-42037)
Disclosures: M.Y.L. has received research support in the form of contributed product from OpGen and Sage Products (now part of Stryker Corporation), and has received an investigator-initiated grant from CareFusion Foundation (now part of BD).
Burden and Trends of Hospital-Associated Community-Onset (HACO) Infections From Antibiotic Resistant and Nonresistant Bacteria
- Babatunde Olubajo, Sujan Reddy, Hannah Wolford, Kelly Hatfield, John Jernigan, James Baggs
-
- Journal:
- Infection Control & Hospital Epidemiology / Volume 41 / Issue S1 / October 2020
- Published online by Cambridge University Press:
- 02 November 2020, p. s145
- Print publication:
- October 2020
-
- Article
-
- You have access Access
- Export citation
-
Background: Studies on the effectiveness of hospital-based interventions often measure hospital-onset infections as the outcome of interest. However, hospital-associated infections may manifest after patient discharge (classified as hospital-associated community-onset, HACO), and the epidemiology may vary by antibiotic resistance (AR) profile. We examined the epidemiology and trends of HACO infections of AR and non–antibiotic-resistant (non-AR) bacteria. Methods: We included clinical community-onset (CO) cultures (obtained sooner than or on day 3 of hospitalization) yielding the bacterial species of interest among hospitalized patients in 260 hospitals in the Premier Healthcare Database from 2012 to 2017. HACO infections were defined as CO cultures in a patient who had a previous hospitalization in the same hospital within 30 days. We examined methicillin resistance among Staphylococcus aureus (MRSA), vancomycin resistance among Enterococcus spp (VRE), carbapenem resistance among Enterobacteriaceae (E. coli, Klebsiella spp, and Enterobacter spp) (CRE), extended-spectrum cephalosporin resistance suggestive of extended-spectrum β-lactamase (ESBL) production in Enterobacteriaceae, carbapenem resistance among Acinetobacter spp (CRAsp), and carbapenem resistance among Pseudomonas aeruginosa (CRPA). We described the proportion of CO infections that were HACO, the proportion of HACO infections from sterile sites, overall HACO rates, and annual trends for sensitive and resistant phenotypes. Generalized estimating equation regression models that accounted for hospital-level clustering were used to estimate annual trends controlling for hospital characteristics and month of discharge. Results: The rate of HACO infections by pathogen ranged from 0.78 to 38.76 per 10,000 hospitalizations; 7%–34% were sterile site infections (Table 1). For each bacterial pathogen, a significantly higher proportion of AR CO infections had a previous hospitalization compared to non-AR CO infections (all χ2, P < .05). The annual trends for AR and non-AR HACO infections between 2012 and 2017 were significantly decreasing for most pathogens, except ESBL HACO infections. Conclusions: Even when using a definition limited to readmission to the same hospital, HACO infections occur commonly with differing rates by pathogen and antibiotic resistance profile. Although these rates are decreasing for most of the pathogens studied, improving surveillance and identifying prevention strategies for these infections are necessary to further reduce the burden of hospital-associated infections.
Funding: None
Disclosures: None
Substance Use Diagnoses Among Persons with Community-Onset Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
- Natalie McCarthy, James Baggs, John Jernigan, Isaac See, Kelly Hatfield, Sujan Reddy, Runa Gokhale, Hannah Wolford, Anthony Fiore
-
- Journal:
- Infection Control & Hospital Epidemiology / Volume 41 / Issue S1 / October 2020
- Published online by Cambridge University Press:
- 02 November 2020, pp. s392-s393
- Print publication:
- October 2020
-
- Article
-
- You have access Access
- Export citation
-
Background: In recent years, the historic declines in the incidence of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSIs) in the United States have slowed. We examined trends in the incidence of community-onset (CO) MRSA BSIs among hospitalized persons with and without substance-use diagnoses. Methods: Using data from >200 US hospitals reporting to the Premier Healthcare Database (PHD) during 2012–2017, we conducted a retrospective study among hospitalized persons aged ≥18 years. MRSA BSIs with substance use were defined as hospitalizations having both a blood culture positive for MRSA and at least 1 International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) or ICD-10-CM diagnostic code for substance use including opioids, cocaine, amphetamines, or other substances (excluding cannabis, alcohol, and nicotine). MRSA BSIs were considered community onset when a positive blood culture was collected within 3 days of admission. We assessed annual trends and described characteristics of CO MRSA BSI hospitalizations, stratified by substance use. Results: Of 20,049 MRSA BSIs from 2012 to 2017, 17,634 (88%) were CO. Overall, MRSA BSI incidence decreased 7%, from 178.5 to 166.2 per 100,000 hospitalizations during the study period; However, CO MRSA BSI rates remained stable (152.7 to 149.9 per 100,000 hospitalizations). Among CO MRSA BSIs, 1,838 (10%) were BSIs with substance-use diagnoses; the incidence of CO MRSA BSIs with substance use increased 236% (from 8.2 to 27.6 per 100,000 hospitalizations) and represented a greater proportion of the CO MRSA rate over the study period (Fig. 1). The incidence of CO MRSA BSIs without substance use decreased 15% (from 144.5 to 122.4 per 100,000 hospitalizations). Patients with CO MRSA BSIs with substance use were younger (median, 40 vs 65 years), more likely to be female (50% vs 40%), white (79% vs 69%), and to leave against medical advice (15% vs 1%). Among patients not leaving against medical advice, CO BSI patients with substance-use diagnoses had longer lengths of stay (median, 11 vs 9 days), lower in-hospital mortality (9% vs 14%), and higher hospitalization costs (median, $22,912 vs $17,468) compared to patients without substance-use diagnoses. Conclusions: Although the overall CO MRSA BSI rate remained unchanged from 2012 to 2017, infections with substance use diagnoses increased >3-fold, and infections without substance use diagnoses decreased. These data suggest that the emergence of MRSA associated with substance-use diagnoses threatens potential progress in reducing the incidence of CO MRSA infections. Additional strategies may be needed to prevent MRSA BSI in patients with substance-use diagnoses, and to maintain national progress in the reduction of MRSA infections overall.
Funding: None
Disclosures: None
Evaluation of Care Interactions Between Healthcare Personnel and Residents in Nursing Homes Across the United States
- Nai-Chung Chang, Karim Khader, Molly Leecaster, Lindsay Visnovsky, Scott Fridkin, Morgan Katz, Philip Polgreen, Mary-Claire Roghmann, Candace Haroldsen, Diane Mulvey, Kristina Stratford, Lauren Dempsey, William Dube, Ghinwa Dumyati, Linda Frank, Deborah Godine, Siyeh Gretzinger, Trupti Hatwar, Marion Kainer, Joseph Kellogg, Sarah Kuchman, Laura LaLonde, Giancarlo Licitra, Ruth Lynfield, J.P. Mahoehney, Joelle Nadle, Sujan Reddy, Nicola Thompson, Rebecca Tsay, Lucy Wilson, Alexia Zhang, Matthew Samore
-
- Journal:
- Infection Control & Hospital Epidemiology / Volume 41 / Issue S1 / October 2020
- Published online by Cambridge University Press:
- 02 November 2020, pp. s36-s38
- Print publication:
- October 2020
-
- Article
-
- You have access Access
- Export citation
-
Background: Certain nursing home (NH) resident care tasks have a higher risk for multidrug-resistant organisms (MDRO) transfer to healthcare personnel (HCP), which can result in transmission to residents if HCPs fail to perform recommended infection prevention practices. However, data on HCP-resident interactions are limited and do not account for intrafacility practice variation. Understanding differences in interactions, by HCP role and unit, is important for informing MDRO prevention strategies in NHs. Methods: In 2019, we conducted serial intercept interviews; each HCP was interviewed 6–7 times for the duration of a unit’s dayshift at 20 NHs in 7 states. The next day, staff on a second unit within the facility were interviewed during the dayshift. HCP on 38 units were interviewed to identify healthcare personnel (HCP)–resident care patterns. All unit staff were eligible for interviews, including certified nursing assistants (CNAs), nurses, physical or occupational therapists, physicians, midlevel practitioners, and respiratory therapists. HCP were asked to list which residents they had cared for (within resident rooms or common areas) since the prior interview. Respondents selected from 14 care tasks. We classified units into 1 of 4 types: long-term, mixed, short stay or rehabilitation, or ventilator or skilled nursing. Interactions were classified based on the risk of HCP contamination after task performance. We compared proportions of interactions associated with each HCP role and performed clustered linear regression to determine the effect of unit type and HCP role on the number of unique task types performed per interaction. Results: Intercept-interviews described 7,050 interactions and 13,843 care tasks. Except in ventilator or skilled nursing units, CNAs have the greatest proportion of care interactions (interfacility range, 50%–60%) (Fig. 1). In ventilator and skilled nursing units, interactions are evenly shared between CNAs and nurses (43% and 47%, respectively). On average, CNAs in ventilator and skilled nursing units perform the most unique task types (2.5 task types per interaction, Fig. 2) compared to other unit types (P < .05). Compared to CNAs, most other HCP types had significantly fewer task types (0.6–1.4 task types per interaction, P < .001). Across all facilities, 45.6% of interactions included tasks that were higher-risk for HCP contamination (eg, transferring, wound and device care, Fig. 3). Conclusions: Focusing infection prevention education efforts on CNAs may be most efficient for preventing MDRO transmission within NH because CNAs have the most HCP–resident interactions and complete more tasks per visit. Studies of HCP-resident interactions are critical to improving understanding of transmission mechanisms as well as target MDRO prevention interventions.
Funding: Centers for Disease Control and Prevention (grant no. U01CK000555-01-00)
Disclosures: Scott Fridkin, consulting fee, vaccine industry (spouse)